Impact of complement and difference of cell-based assay and ELISA in determination of neutralization capacity against mumps and measles virus.


Journal

Journal of immunological methods
ISSN: 1872-7905
Titre abrégé: J Immunol Methods
Pays: Netherlands
ID NLM: 1305440

Informations de publication

Date de publication:
03 2021
Historique:
received: 07 08 2020
revised: 29 12 2020
accepted: 31 12 2020
pubmed: 8 1 2021
medline: 15 9 2021
entrez: 7 1 2021
Statut: ppublish

Résumé

Neutralizing antibodies against mumps and measles virus are considered a correlate of protection against these diseases. Measurement of neutralizing antibodies is mostly performed using plaque reduction neutralization assay or 50% cell culture infective dose (CCID

Identifiants

pubmed: 33412172
pii: S0022-1759(21)00002-8
doi: 10.1016/j.jim.2021.112957
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Complement System Proteins 9007-36-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112957

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Marija Brgles (M)

University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, HR-10000 Zagreb, Croatia. Electronic address: mbrgles@unizg.hr.

Tihana Kurtović (T)

University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, HR-10000 Zagreb, Croatia.

Maja Lang Balija (M)

University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, HR-10000 Zagreb, Croatia.

Ana Hećimović (A)

Croatian Institute for Transfusion Medicine, Petrova 3, HR-10000 Zagreb, Croatia.

Tatjana Mušlin (T)

Croatian Institute for Transfusion Medicine, Petrova 3, HR-10000 Zagreb, Croatia.

Beata Halassy (B)

University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, HR-10000 Zagreb, Croatia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH